Table 2.

Odds ratio and 95% CI for BM fibrosis change according to therapy (ruxolitinib vs BAT)

BM fibrosis	Ruxolitinib vs BAT, n	Odds ratio†	95% CI
Worsening*
24 months	18/51* vs 39/64*	0.38	0.17–0.84
48 months	8/32* vs 35/46*	0.11	0.01–0.32
60 months	6/23* vs 21/78*	0.07	0.01–0.34‡
Improvement**
24 months	10/6 vs 6/98	3.10	1.01–9.50
48 months	13/38 vs 13/65	99.05	8.47–> 999
60 months	9/25 vs 1/31	19.29	2.13–174.89
Improvement or stabilization**
24 months	50/68 vs 59/98	2.62	1.20–5.73
48 months	30/38 vs 30/65	9.40	3.18–27.79
60 months	19/25 vs10/31	15.39	2.97–79.67‡

CI confidence interval

*Patients with baseline BM fibrosis grade 3 were excluded from this analysis because further progression is not defined. An odds ratio < 1.0 favors ruxolitinib over BAT

**An odds ratio > 1.0 favors ruxolitinib over BAT

^†Odds ratio determined by logistic regression controlled for baseline BM fibrosis grade

^‡The last available grade from 54, 60, or 66 months was used